💉Exclusive Patent License Opportunity for Cancer Treatment Drug Delivery
Prospective Grant of an Exclusive Patent License: Size-Dependent Brain and Lymphatic Distribution of Macromolecular Drug Delivery Platform
Summary
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents applications listed in the Supplementary Information section of this notice to Sangam Lifesciences, Inc. (Sangam), a company located in Denver, Colorado.
Agencies
- Health and Human Services Department
- National Institutes of Health
Business Impact
$$$ - High
The document outlines a prospective exclusive patent license for a drug delivery platform, creating potential opportunities for businesses in biotech and pharmaceuticals to develop, manufacture, and commercialize related products. The license is royalty-bearing and may have broad implications for financial planning and strategic partnerships in these sectors.